Study aim: Evaluation of the effects of Ginger on clinical symptoms and laboratory signs in patients with COVID-19 Design: A phase 3, Placebo-controlled, Paralleled, double-blind, randomized clinical trial, 84 patients, randomized using blocks Settings and conduct: This study will be conducted at the Shahid Mohammadi Hospital, Hormozgan University of Medical Sciences, Bandar Abbas.The study population is 84 patients with COVID-19 (42 patients in control group and 42 in study group). Participants/Inclusion and exclusion criteria: Inclusion criteria: Patients with positive polymerase chain reaction (PCR) test for COVID-19 or/and lung involvement in imaging, age ≥18 years, primary clinical symptoms, non-hospitalized mild, and signing informed consent. Exclusion Criteria: Patients with underlying diseases, includingchronic hepatitis, cirrhosis, cholestatic liver diseases, cholecystitis, and peptic ulcers, use of anticoagulant drugs like warfarin, and hormonal drugs, history of allergy to ginger, and pregnancy and breastfeeding Intervention groups: Group A will be patients receiving standard treatment of COVID-19 according to the Ministry of Health's protocol. Group B will be patients receiving, in addition to the standard treatment, a ginger-based herbal tablet, at a dose of 1000 mg three times a day for a period of seven days. Main outcome variables: Checking the SARS-CoV-2 clearance, improvement of fever Evaluation of white blood cell count Requremet for hospital admission Occurrence of adverse drug reactions